Article

Bbarrons.com on 2019-09-12 17:51

Buy AbbVie, Because Its Deal for Allergan Just Might Work, Analyst Says

UBS analyst Navin Jacob estimates that a combined AbbVie and Allergan will have a 9% free cash flow in 2023 and that from there on it will have ...

Related news

Botox Maker Allergan Is Sold to AbbVie in $63 Billion Deal The New York Times
Chicago , Ireland , United States , Europe
BAbbVie Is Buying Allergan and Wall Street Is Doubtful barrons.com
Europe , Wall Street
BAbbVie Winning Over Skeptics As Analysts Warm To Allergan Deal barrons.com
BAbbVie Stock Is Falling Because Investors Hate the Allergan Deal. The Vice Chairman Bought Up Shares barrons.com
Stock Island
AbbVie to buy rival pharmaceutical company Allergan in “transformative” deal valued at $63 billion reviewtimes.com
BBuy Deere Stock Because There Will Be No Global Recession, Analyst Says barrons.com
China , Midwest , Wall Street
MAbbVie closes acquisition of Allergan marketwatch.com
San Francisco , New York
FPfizer in talks to buy Allergan ft.com
Wall Street , Ireland , New York
BBuy Gilead Because Remdesivir Is Worth Billions, Analyst Says barrons.com
Wall Street , Europe
BAbbVie Shareholders Can't Vote on Allergan Acquisition barrons.com
Wall Street
MÄRKTE-AbbVie-Offerte beflügelt Botox-Macher Allergan Reuters
FPowell, FedEx, Abbvie sinks on Allergan deal ft.com
Hong Kong
BBuy AbbVie Stock Because You ‘Can’t Ignore’ How Cheap It Is barrons.com
Allegan
BBuy Amazon Because Its Cloud Business Will Soar, Analyst Says barrons.com
Wall Street
BBuy Micron Stock Because Memory Pricing Will Stabilize, Says Analyst barrons.com
Wall Street
BBuy Netflix Because of Its New Popular Shows, Analyst Says barrons.com
Wall Street
BBuy Uber Stock Because Its Business Is Healthy, Analyst Says barrons.com
Wall Street , India
BBuy Amarin Because It Is Cheap, Analyst Says barrons.com
Far Enough
AbbVie will Botox-Hersteller Allergan für 63 Mrd Dollar schlucken Reuters
Europe , Wall Street , Massachusetts , Medford